BELIEF trial published
The addition of bevacizumab to erlotinib improves progression-free survival for patients with advanced NSCLC harbouring activating EGFR and T790M mutation. Results from the BELIEF trial published in Lancet Respiratory Medicine: http://dx.doi.org/10.1016/S2213-2600(17)30129-7
6th ETOP Residential Workshop, 5-7 Oct, Amsterdam - Application open
The Lancet Summit: COPD and Lung Cancer
This new Summit, organised by The Lancet Respiratory Medicine and The Lancet Oncology, will cover all of the main areas of debate for patients with COPD and lung cancer from prevention, diagnosis, treatment through to palliative care.
ELCC 2017 - Register now
ESMO and IASLC are pleased to announce the 7th edition of the European Lung Cancer Conference (ELCC). Register now!
Save the Dates! ETOP Annual Meeting and ETOP Residential Workshop 2017
The next ETOP Annual Meeting takes place in Zurich, CH on 10/11 November 2017 and the next ETOP Residential Workshop in Amsterdam, NL on 5-7 October 2017.